Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost

The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients

“…In regulatory trials, bimatoprost (45%) has been previously shown to cause more conjunctival hyperaemia than latanoprost (5-15%). [18][19][20][21] In direct comparative trials, Stewart and coworkers 22 and Parrish and coworkers 23 found significantly greater conjunctival hyperaemia in normal subjects and primary open-angle glaucoma patients with travoprost and bimatoprost. The ocular irritation finding in this survey appears to be new and not to have been noted as different among the prostaglandins in previous clinical trials.…”

The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension

“…[1][2][3][4] However, local adverse effects have been reported with PG analogues, including conjunctival hyperemia, iris hyperpigmentation, and eyelash growth. 1,[5][6][7] Among the serious PG-induced side effects are the disruption of the blood-aqueous barrier (BAB) and the development of cystoid macular oedema (CME), which have been described in susceptible eyes, especially in aphakic or pseudophakic patients. [8][9][10][11][12][13][14][15][16][17] However, there is controversy regarding the effects of PG analogues on the BAB of phakic patients with no previous history of surgery or uveitis.…”

A comparison of the efficacy of latanoprost, travoprost and bimatoprost in open angle glaucoma and ocular hypertension

“…Parrish et al (2003) reported the incidence of hyperemia to be 47.1% with latanoprost, 58.0% with travoprost and 68.6% with bimatoprost. Also, several studies reported less hyperemia with latanoprost compared to travoprost or bimatoprost (Stewart et al, 2003;Ozdemir et al, 2004;Sarıcaoğlu et al, 2005;Sen et al, 2006). However, Whitson et al (2010) observed no significant differences between bimatoprost, latanoprost, and travoprost regarding objective clinical measures of ocular tolerability, including physician-graded hyperemia, corneal staining and tear breakup time after 3 months of treatment.…”